FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 32350104

Estimated average burden
hours per response: 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MacDonald Stephen G.	2. Date of Requiring (Month/Da 02/24/20	Statement y/Year)	3. Issuer Name and Ticker or Trading Symbol Eloxx Pharmaceuticals, Inc. [ELOX]					
(Last) (First) (Middle) C/O ELOXX			4. Relationship of Reporting Issuer (Check all applicable)	10% Owner Other (specify below)		5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person		
PHARMACEUTICALS, INC. 950 WINTER STREET (Street) WALTHAM MA 02451	_		Director X Officer (give title below) VP Finance & Acct					
(City) (State) (Zip)	-							
Table I - Non-Derivative Securities Beneficially Owned								
			2. Amount of Securities Beneficially Owned (Instr. 4)	Form: D (D) or Ir			Nature of Indirect Beneficial wnership (Instr. 5)	
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)								
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise		5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr.
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security		Direct (D) or Indirect (I) (Instr. 5)	5)
Employee Stock Option (Right to Buy)	(1)(2)	10/21/2029	Common Stock	15,000	3.93		D	
Employee Stock Option (Right to Buy)	(1)(3)	03/11/2030	Common Stock	27,500	2.88		D	
Employee Stock Option (Right to Buy)	(1)(4)	04/02/2030	Common Stock	14,100	1.5	9	D	

Explanation of Responses:

- 1. The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan.
- 2. The option vests and becomes exercisable over a four-year period, with one-fourth of the shares of common stock underlying the options vesting on October 21, 2020, and the remainder vests in twelve equal quarterly installments thereafter, subject to Reporting Person's continuous service as of each such date.
- 3. The option vests and becomes exercisable over a two-year period as follows: two-fifths (2/5) of the shares underlying the option shall vest on March 11, 2021, another two-fifths (2/5) shall vest on September 11, 2021 and the remainder of the grant shall vest on March 11, 2022, subject to Reporting Person's continuous service as of each such date.
- 4. The option vests and becomes exercisable over a four-year period, with one-fourth of the shares of common stock underlying the options vesting on April 2, 2021, and the remainder vesting in twelve equal quarterly installments thereafter, subject to Reporting Person's continuous service as of each such date.

/s/ Stephen G. MacDonald 01/22/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

(For Executing Form ID, Forms 3, 4 and 5 and Schedule 13D and 13G)

Know all by these presents that the undersigned hereby constitutes and appoints each of Miguel Vega and Lily Colahan of Cooley LLP; and Gregory Williams, Neil Belloff and John Green of Eloxx Pharmaceuticals, Inc. (the "*Company*"), the undersigned's true and lawful attorneys-in-fact and agents to:

- (1) Prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the the Securities and Exchange Commission (the "SEC") Form ID, Uniform Application for Access Codes to File on EDGAR, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 13 and Section 16(a) of the Securities Exchange Actof 1934, as amended (the "Exchange Act"), or any rule or regulation thereunder;
- Prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the SEC Forms 3, 4 and 5 (including amendments thereto and joint filing agreements in connection therewith) in accordance with Section 16(a) and the rules and regulations thereunder in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of the Company and Schedule 13D or 13G (including amendments thereto and joint filing agreements in connection therewith) in accordance with Section 13 of the Exchange Act and the rules and regulations thereunder;
- (3) Do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare and execute any such Form ID and Forms 3, 4 or 5 or Schedule 13D or 13G (including amendments thereto and joint filing agreements in connection therewith) and file such forms with the SEC and any stock exchange, self-regulatory association or any similar authority; and
- (4) Take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required of the undersigned, it being understood that the documents executed by the attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as the attorney-in-fact may approve in the attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, and their substitutes, in serving in such capacity at the request of the undersigned, are not assuming (nor is the Company assuming) any of the undersigned's responsibilities to comply with Section 13 and Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Form ID or Forms 3, 4 and 5 or Schedule 13D or 13G with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date written below.

Date: January 8, 2021 Signature: /s/ Stephen G. MacDonald

Name:_ Stephen G. MacDonald